Peyronie's Disease: Non-Surgical Treatment Options

Dr. Luis Casavantes | Dr. Palmira Morales
Avanti Derma, Tijuana, Mexico

Peyronie's disease is characterized by the formation of fibrous plaque within the tunica albuginea, producing penile curvature, deformity, pain, and — in many patients — erectile dysfunction. Surgical correction has historically been the definitive treatment, but the range of non-surgical options has expanded significantly in the past decade, and for many patients they are the appropriate first line.

The Two Phases of Peyronie's

Peyronie's disease has a distinct acute (active) phase and a chronic (stable) phase. The acute phase — typically 6–18 months — is characterized by pain, active plaque formation, and evolving curvature. The chronic phase is characterized by stable curvature and plaque without pain.

Treatment choice is phase-dependent. Interventions that make clinical sense in the acute phase may not in the chronic, and vice versa.

Oral Therapy

Pentoxifylline, L-carnitine, vitamin E, and CoQ10 have been used with modest evidence in the acute phase. The individual evidence for each is limited; combination protocols have been studied with mixed results. Oral therapy is best considered as adjunctive to definitive treatment rather than as definitive treatment itself.

Intralesional Injection

Collagenase clostridium histolyticum (Xiaflex). The only FDA-approved intralesional therapy for Peyronie's disease. It enzymatically breaks down collagen within the plaque, reducing curvature over a course of injections. Indicated for stable-phase patients with curvature between 30° and 90°.

Interferon alfa-2b. Off-label but with supportive evidence for curvature reduction in the acute and stable phases.

Verapamil. Off-label; older data support modest efficacy.

Traction Therapy

Penile traction devices, used consistently over 3–6 months, have evidence for curvature reduction and length preservation, particularly when combined with intralesional therapy or after surgical repair. Compliance is the primary limitation — traction requires daily use for several hours over months to produce meaningful change.

Regenerative Approaches

Regenerative modalities — PRP, shockwave and stem cell therapy — are being investigated for Peyronie's disease with early promising results, particularly in the acute phase and for concurrent erectile dysfunction. These are not first-line treatments and should not be marketed as definitive therapy. In the right patient, at the right phase, they may be a useful adjunct.

Concurrent Erectile Dysfunction

A significant proportion of Peyronie's patients have concurrent erectile dysfunction. Treatment planning should address both simultaneously. PDE5 inhibitors, low-intensity shockwave therapy, and regenerative modalities are all part of the concurrent-ED toolkit.

When Surgery Is the Right Answer

Surgery remains the definitive treatment for:

• Stable curvature exceeding what non-surgical therapy can correct.

• Complex deformity (hourglass, indent, hinge effect).

• Concurrent severe ED not responsive to medical management (penile prosthesis with or without concurrent corporoplasty).

Non-surgical options are not universally superior. They are appropriate for a large subset of patients and inadequate for another.

The Selection Question

The question of whether to pursue non-surgical or surgical treatment for Peyronie's disease is a clinical one, informed by phase, curvature severity, concurrent ED, plaque location, and patient priorities. It is not a marketing decision.

Clinical Takeaways

• Peyronie's disease has two clinically distinct phases; treatment choice is phase-dependent.

• Xiaflex is the only FDA-approved intralesional therapy and is indicated for stable-phase curvature.

• Traction therapy has evidence but requires committed patient compliance.

• Regenerative approaches (PRP, shockwave, stem cells) are adjunctive, not definitive.

• Surgery remains the appropriate answer for severe curvature, complex deformity, or concurrent severe ED.

Bibliography

1. Nehra, A., et al. "Peyronie's Disease: AUA Guideline." J Urol 194 (2015): 745–753.

2. Levine, L.A., Larsen, S.M. "Surgery for Peyronie's Disease." Asian J Androl 15 (2013): 27–34.

3. Ziegelmann, M.J., Bajic, P., Levine, L.A. "Peyronie's Disease: Contemporary Evaluation and Management." Int J Urol 27 (2020): 504–516.